Curr Pathobiol Rep (2013) 1:53–62
DOI 10.1007/s40139-012-0005-4
miRNA IN PATHOBIOLOGY (T PATEL, SECTION EDITOR)
MicroRNAs in Liver Health and Disease
Shu-hao Hsu • Kalpana Ghoshal
Published online: 13 January 2013
Springer Science+Business Media New York 2013
Abstract MicroRNAs (miRNAs), a class of short noncoding RNAs, have been studied intensely and extensively
in the past decade in every aspect of biological processes,
including cell differentiation, proliferation and death.
These findings pointed out the pivotal role of miRNA in
posttranscriptional control of gene expression in animals
and established miRNAs as therapeutic targets for different
pathophysiological processes, including liver disease. Here
we have discussed the recent advances made in identifying
the miRNAs deregulated in different liver diseases such as
obesity, hepatitis, alcoholic and nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma, as well as
pathophysiological conditions such as developmental
abnormality. We have specifically reviewed the role of
miRNAs in these diseases and discussed critically potential
impacts of these miRNAs as biomarkers and/or therapeutic
targets in liver pathobiology in the clinical setting. Finally,
we have highlighted the latest techniques or preclinical
and/or clinical trials that are being developed to replenish
or inhibit the deregulated miRNAs.
S. Hsu
Department of Molecular and Cellular Biochemistry,
The Ohio State University, Columbus, OH 43210, USA
S. Hsu (&) K. Ghoshal
Comprehensive Cancer Center, The Ohio State University,
420 West 12th Avenue, 606 TMRF Building, Columbus,
OH 43210, USA
e-mail: cothuho@gmail.com
K. Ghoshal
Department of Pathology, The Ohio State University,
Columbus, OH 43210, USA
Keywords microRNA miRNA Liver development
Metabolism Hepatitis, Fibrosis Hepatocellular
carcinoma HCC CC Liver disease Gene therapy
Pathobiology
Introduction
MicroRNAs (miRNAs) are short noncoding RNAs consisting of about 22 nucleotides that negatively regulate
expression of protein-coding genes. Although miRNAs are
predominantly transcribed into primary miRNAs (primiRNA) by RNA polymerase II, a few are transcribed by
RNA polymerase III. The mechanism of transcriptional
regulation of miRNAs is not fully determined, because
identification of the miRNA promoters is still a challenging
task [1–3]. The pri-miRNA is processed by Drosha, a
RNAse III ribonuclease, and its partner DGCR8 [4, 5] to
generate pre-miRNA, which is then transported from the
nucleus to cytoplasm by Exportin-5 [6]. In cytoplasm,
Dicer, also an RNAse III endonuclease, interacts with
TRBP (Tar RNA binding protein) to mediate further processing of pre-miRNA to a *22 nucleotide miRNA duplex
[7]. The single-stranded mature miRNA is then incorporated into effector complexes known as miRISC (miRNAinduced silencing complex) to suppress gene expression
[8]. Generally, miRNAs regulate gene expression in animal
cells by inhibiting translation and/or inducing decay of
target mRNAs [9]. The deregulated miRNAs may lead to
abnormal expression of their target genes and finally lead
to diseases. Here, the discussion is focused on the deregulation of miRNAs in liver diseases (Fig. 1) and the
potential therapeutic strategies developed from these
findings.
123
54
Curr Pathobiol Rep (2013) 1:53–62
Fig. 1 Summary of deregulated miRNAs identified in different liver disease. The arrow indicates the abnormal expression pattern of each
miRNA in the designated disease. Red, upregulated; Green, downregulated. (Color figure online)
Role of miRNAs in Liver Development
miRNAs are known to be important in the regulation of
organ development and cell differentiation. For example,
lin-4 and let-7, two of the founding members of miRNAs
identified in C. elegans [10], were critical components to
regulate different stages of development in C. elegans.
Loss-of-function mutations in lin-4 and let-7 genes lead to
delayed development at early larval and late-larval/adult
stages, respectively, whereas increased expression of these
miRs accelerates development of the organism. Similarly,
the early embryonic lethality of Dicer 1 knockout mice
confirmed its essential role in mammalian development
[11]. However, its role in liver development has not been
addressed because two studies that have reported phenotype of liver-specific Dicer 1 knockout mice used Alb-Cre
mice where the gene is deleted after the development of the
liver bud [12•, 13]. Crossing Dicer 1 floxed mice to AfpCre or Foxa3-Cre may be helpful to address the role of
miRNAs in liver development. Apparently normal liver
morphology in mice with deleted miR-122, the most
abundant, highly conserved, liver-specific miRNA, demonstrated that miR-122 is not essential for embryonic liver
123
development [14••, 15••]. However, it is likely that there
are functional redundancies among liver-specific miRs
complementing the function of miR-122 during development, which can be addressed by deleting several fetal
liver-specific miRNA genes in combination in mice.
Recent studies from several labs, including ours, have
established essential role of miR-122 in maintaining the
differentiation state of the liver, since its loss induced
proliferation of oval and bile duct cells in young adult mice
and hepatocellular carcinoma HCC with age [14••]. In
addition to miR-122, several other miRNAs appear to be
involved in liver differentiation. Antisense oligo (ASO)
mediated knockdown of miR-30a, specifically expressed in
the ductal plate and the bile duct, results in defects in the
intrahepatic bile duct and canaliculi in zebrafish [16].
Furthermore, the miR-23b cluster downregulates TGF-b/
BMP signaling, which governs differentiation of hepatocytes and cholangiocytes [17, 18] by silencing Smad 3, 4
and 5 [19]. It is proposed that the gradient expression of
miR-23b clusters negatively regulate TGF-b expression
and promote terminal differentiation of bi-potential hepatoblasts to hepatocytes instead of bile duct cells. Many
studies have revealed differential expression of miRNAs
Curr Pathobiol Rep (2013) 1:53–62
between embryonic and adult livers and correlated their
findings with the critical factors involved in liver development. However, the expression of miRNA often observed in
the total liver RNA may not reflect the actual biological role
of differentially expressed miRNA in specific cell types.
Therefore, it is necessary to analyze the miRNA expression
at different stages of liver development by monitoring their
expression in specific cell types by in situ hybridization or
real-time RT-PCR in a purified cell population. Also, in
absence of knockout animal models, it is difficult to pinpoint the developmental role of these miRs.
miRNAs in Obesity and its Associated Complications
Partly due to changed dietary habits of excessive high
caloric intake and inactive lifestyles [20], obesity has
become a major health problem by causing cardiovascular
disorders such as atherosclerosis [21] or metabolic disorders such as type II diabetes [22]. Obesity is mainly
induced by excessive storage of energy in adipose tissue
and a subsequent increase in the size and number of adipocytes. Excessive production and storage of energy are
frequently associated with abnormal lipid metabolism in
the liver resulting from miRNA deregulation. Among the
deregulated miRNA in obese mouse model, miR-34a has
been reported to be the most highly elevated hepatic miR.
Antisense mediated miR-34a inhibition restored hepatic
expression of b-Klotho, a critical enzyme in bile acid/
cholesterol metabolism [23], and improved FGF19 signaling pathway that mediated postprandial response and
decreased liver fat [24]. FGF19 signaling is frequently
impaired in patients with liver steatosis. Overexpression of
let-7a in the pancreas leads to decreased fat mass, body
weight and size through enhanced glucose tolerance.
Knockdown of let-7 by antisense oligonucleotides prevents
obesity-induced glucose intolerance and steatosis [25]. The
control of let-7a over glucose homeostasis is partly through
targeting the insulin receptor (Insr) and insulin receptor
substrate 2 (Irs2). Similarly, silencing of miR-103/107,
both abnormally upregulated in an obese mouse model,
leads to insulin sensitivity and improves glucose homeostasis [26]. This effect appears to be through its direct
target, caveolin-1, which is an important regulator of
insulin receptors [26].
miRNAs that regulate lipid metabolism by targeting
several key genes have been extensively studied [27]. MiR122 has been one of the most widely studied miRNAs that
affects lipid metabolism [28, 29]. Esau et al. first showed
that the application of a modified antisense oligonucleotide
(ASO) against miR-122 efficiently downregulated serum
cholesterol in high-fat diet fed mice [28]. ASO-mediated
depletion of miR-122 activated AMPK and led to elevated
55
fatty acid oxidation and inhibition of cholesterol synthesis
in the liver. AMPK is known to be a master regulator of
metabolism in different organs, including muscle, brain
and liver [30], and has been considered as a therapeutic
target for obesity-induced type II diabetes. The anti-diabetic drug metformin functions by activating AMPK signaling pathway, leads to reduced glucose synthesis in liver
and ameliorates insulin resistance in muscle. In the light of
this study by Esau et al. on the effect of miR-122 on
AMPK, miRNAs can also be considered as an option to
treat obesity-induced disease through AMPK activation in
the liver. Recently, miR-199a-3p, miR-195, and miR-451
were shown to target upstream kinase activating AMPK,
including LKB1 [31] in hepatocytes and MO25 in glioma
cells [32].
On the other hand, genes involved in lipid metabolism
may function by regulating miRNA expression. For
example, it has been shown that activation of SREBP1 and
SREBP2, which modulate cholesterol homeostasis by
activating sterol-regulated genes, induce transcription of
miR-33a and miR-33b, located within the intronic region of
SREBP2 and SREBP1, respectively [33•]. MiR-33a/b were
shown to target ABCA1, involved in cholesterol efflux.
Inhibition of miR-33 by ASO further reversed the cholesterol efflux to prevent atherosclerosis in mice [34••] and
raised plasma HDL-associated cholesterol (HDL-C) and
VLDL-associated triglyceride in non-human primates [35].
These findings further highlighted the therapeutic potential
of miRNAs in the treatment of athesclerosis by regulating
HDL-C. It is clinically feasible to target several key
miRNAs simultaneously to control the activity of key
regulators in lipid metabolism, such as AMPK, which is an
important drugable target for pharmaceutical companies.
However, most of the research has been focused on the
effect of single miRNAs on one aspect of metabolism, and
it is too early to speculate on the outcome of treatment
targeting multiple miRNAs. Thus, it is necessary to
establish a ‘‘miRNAomic’’ analysis in patients with metabolic disorders in order to fully understand which group of
miRNAs are the most critical targets associated with the
designated diseases. Furthermore, from the intriguing study
made by Gatfield et al. [36•] on the role of miR-122 in
hepatic circadian gene expression, we should be aware that
temporal expression pattern of miRNAs may be key to the
fine tuning of metabolism and can be used to accurately
detect or prevent metabolic disorder.
Role of miRs in Viral Hepatitis
Hepatitis is predominantly caused by hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection. Although
there are effective therapies to inhibit viral replication,
123
56
none are curative because viruses often develop resistance
to these drugs. Several important findings on the implication of miR-122 in HCV replication highlighted the
potential of miRNAs in the development of anti-viral
therapy. The seminal discovery by Jopling et al. [37]
demonstrating essential role of miR-122 in the replication
of HCV RNA in hepatic cells was instrumental in the
development of Miravirsen, a modified anti-miR-122 oligonucleotide by Santaris Pharma, currently undergoing
phase II clinical trials in HCV-infected patients. MiR-122
binds to two cognate sites located in the proximal 50 -end of
the viral genome to protect it from 50 to 30 exonuclease
activity or cytoplasmic sensors of viral RNA, and subsequently to facilitate replication [37]. Mutation of miR-122
binding sites on HCV 50 UTR significantly inhibits HCV
viral RNA loading, which can be restored by the overexpression of miR-122 oligonucleotides containing compensatory mutated 30 UTR. This specific interaction between
miR-122 and HCV makes miR-122 an ideal target for the
development of anti-HCV therapy. Liver-specific delivery
of Miravirsen, a locked nucleic acid phosphorthioate
modified antisense oligonucleotide (LNA–ASO), was
developed to effectively targets miR-122 in hepatocytes
after systemic delivery [38••, 39].
In contrast to HCV, much less progress has been made
on the development of miRNA based anti-HBV therapy.
To identify miRs critical for HBV replication, 328 human
miRNAs were individually knocked-down in HepG2.2.15
cells that are genetically designed to support replication of
HBV genome. Among these, loss of miR-199a-3p and
miR-210 reduced viral replication by targeting HBV S
protein (HBsAg) and HBV e antigen (HBeAg), respectively. Further, certain miRNAs indirectly regulate several
critical host proteins involved in HBV replication. Cyclin
G1 was previously identified as a miR-122 target, and it
regulates HBV replication by blocking p53-mediated
inhibition of HBV transcription [40]. MiR-372/373 was
shown to promote HBV expression in HepG2.2.15 cells by
targeting the transcription factor NFIB [41]. Our previous
study also reported that miR-155 negatively regulated
CCAAT/enhancer binding protein beta (C/EBPb), which
activates HBV transcription by binging to its core and S
promoters [42, 43]. Moreover, miRNA may regulate HBV
replication indirectly. For example, ectopic expression of
miR-1 resulted in marked increase of HBV replication by
inducing HBV transcription through indirect augmentation
of farnesoid X receptor expression [44]. These findings
shed further light on the development of miR-based HBV
therapy. However, the majority of the studies on the
mechanism of HBV were based on human HCC cell lines
due to limited availabilities of animal models that can be
naturally infected by HBV [45, 46]. Therefore, it will be
necessary to perform these studies in primates or animal
123
Curr Pathobiol Rep (2013) 1:53–62
models with humanized livers [47] to further extend and
confirm these studies in vivo.
Role of miRs in Liver Fibrosis
Liver fibrosis and subsequent cirrhosis usually predispose
humans to liver cancer or liver failure due to the pro-tumorigenic microenvironment caused by fibrotic tissues surrounding
hepatocytes [48]. Therefore, therapeutic strategies targeting
fibrosis are critical for the prevention of cirrhosis and the
transformation of normal hepatocytes into cancer cells.
When the liver is exposed to chronic damage or
inflammation, fibrosis develops through the excessive
accumulation of extracellular matrix (ECM) secreted by
hepatic stellate cells (HSC). Numerous studies have suggested that miRNAs play a critical role in the activation of
HSC and the secretion of ECM. Recent studies from our
and other laboratories have shown that an increased
occurrence of fibrosis accompanied by steatohepatitis was
observed on miR-122 knockout mice [14••, 15••]. The onset
of hepatic fibrosis after miR-122 depletion may be partially
due to the increased expression of Klf6, which is a zinc
finger transcription factor and a tumor suppressor [15••].
However, reduction of Klf6 was also shown to promote
fibrosis in a rodent chronic liver injury model [49].
The expression of miRNAs involved in fibrosis was
shown to be regulated by several genes. In liver specific
Mdm2 deleted mice, Mdm2-mediated p53 degradation was
impaired and resulted in spontaneous fibrosis through
repressing miR-17-92, which targets connective tissue
growth factor, a master regulator of fibrosis [50]. In hepatic
stellate cells, miR-29 was downregulated by transforming
growth factor beta (Tgf-b) and inflammation. The reduced
miR-29 expression resulted in higher expression of collagen genes, including Col1a1, Col4a5, and Col5a3 [51].
Similar observation was made in pulmonary fibrosis [52].
Furthermore, enhanced fibrosis and mortality were reported
in hepatocyte-specific miR-29 knockout mice in response
to carbon tetrachloride, and altered expression of genes
implicated in fibrosis such as Pdgf [53]. These findings
suggested knockdown of miR-29 via ASO could be
potential new therapeutic target for fibrosis.
Another causal factor in hepatic fibrosis is inflammation.
HSC can be activated by inflammatory cytokines such as
TNF-a, IL-6, IL-1, and CC-chemokine ligand 2 (CCL2) [54].
Interestingly, our studies have shown that hepatic CCL2 is a
direct target of miR-122 and upregulated in miR-122
knockout mice, which is responsible for the hepatic
recruitment of CD11bhighGr-1? neutrophil/monocytes
known to cause inflammation by secreting pro-inflammatory
cytokines [14••]. Since reversal of fibrosis can be achieved by
switching activated HSCs to quiescent status [55], it should
Curr Pathobiol Rep (2013) 1:53–62
be feasible to reverse fibrosis by the delivery of miRNAs,
such as miR-122, targeting cytokines/chemokines that activate HSCs. Furthermore, miRNAs could be a diagnostic
biomarker for liver fibrosis. For example, miR-199a-5p/
199a-3p and miR-221/222 were found to be upregulated in
fibrotic human liver and mouse models of liver fibrosis [56].
Interestingly, miR-222 expression in HSCs is transcriptionally upregulated by NF-jB [57] and NF-jB activator, TNF-a
and TGF-a [56]. NF-jB is a critical factor activating stellate
cells in the process of fibrogenesis [58, 59]. These studies
suggested that miR-221/222 is a good biomarker for activated HSCs and fibrosis. From all these evidence, it is
apparent that miRNAs are likely to be promising therapeutic
targets since they are critical regulators of HSC activation.
miRNAs as Biomarkers and Therapeutic Targets
in HCC
Carlo Croce’s group was the first to connect miRNAs to
cancer by means of a large number of studies in the
miRNA field, which are focused on identifying miR signature associated with different cancers, because of miRNA profiling is more reproducible than mRNA profiling
because of its higher stability, and because it can be done
with paraffin-embedded tissue sections.
Like mRNAs, miRs can also function as oncogenes or
tumor suppressors depending upon the cellular context.
Development of spontaneous tumors induced by deletion of a
single miRNA, miR-122, in the liver indicates that this miRNA indeed functions as a tumor suppressor [14••, 15••]. MiR122 knockout mice independently developed by us and by
Ann-Ping Tsou’s group, are the first HCC model organism
based on miRNA deletion. MiR-122, the most abundant
miRNA in liver, was first suggested as a tumor suppressor in
liver due to its diminished expression in primary HCCs of
human and rodent origin, and its ectopic expression studies in
HCC cell lines and xenograft models [60, 61]. Loss of miR122 results in the upregulation of its target genes, including
Adam10/17, Igf1R, Srf, and Ccng1 [61], and inhibits tumorigenic properties of HCC cells. In addition, miR-199a-3p, also
abundantly expressed in the liver, was significantly suppressed in 40 HBV-related HCC specimens [62]. Similarly,
miR-199a-3p deficiency induces ERK signaling pathway
partly through targeting PAK4. Moreover, the miRNAs
analysis of a large cohort of HCC patients with radical tumor
resection revealed that miR-26a/b were significantly suppressed in tumors compared to noncancerous tissues [63]. Ji
et al. [63] proposed that the miR-26a deficiency may promote
tumorigenesis by the activation of NF-jB and IL-6 signaling
pathways. Dramatic tumor suppression by the adeno-associated viral delivery of miR-26a in a Myc driven mouse model
of HCC further suggests that miR-26a may inhibit tumor
57
growth by directly targeting genes involved in the control of
cell cycle, such as Ccnd2 and Ccne2 [64••].
Similar to the studies with tumor suppressor miRNAs,
many studies were conducted to discover the oncogenic
miRNAs. MiR-21, which is widely upregulated in different
types of cancers, was upregulated in human HCC and may
promote tumor growth by targeting phosphatase and tensin
homolog (PTEN). PTEN is an important suppressor that is
involved in suppression of cell migration and invasion by
inhibiting its downstream targets including FAK, MMP2
and MMP9 [65]. Furthermore, in a choline-deficient and
amino-acid-defined (CDAA) diet-induced HCC model,
many oncogenic miRNAs, including miR-155, miR-221/
222, miR-21 and miR-181b/d, were upregulated at an early
stage of hepatocarcinogenesis [66–69]. Interestingly, these
miRs were reported to target tissue inhibitor of metalloprotease 3 (TIMP3) [67–69], which is involved in tumor
invasion and metastasis as PTEN. Notably, miR-122 was
not associated with any region with frequent chromosomal
loss, which suggests the loss of miR-122 expression in
HCC may not be due to chromosomal aberrations. Taken
these findings together, it is clear that the deregulation of
miRNAs contributes to the hepatocarcinogenesis. However, it is necessary to generate animal models ectopically
expressing or deplete of these deregulated miRNA, since
many of their proposed functions were concluded based on
in vitro studies in HCC cell lines. Without direct evidence
demonstrating that these aberrantly expressed miRNAs are
causally linked to HCC development in vivo, it would be
premature to translate these findings into HCC therapy.
MicroRNA Therapeutics for Liver Disease
With the advent of onco- and tumor suppressor-miRs, much
interest has been focused on taking microRNAs from the
bench to the bedside. The advantages of miR-based therapies
are their smaller size and their ability to regulate a large
number of cellular targets. Different strategies to deliver miRmimics or inhibitors are being explored to restore gene
deregulation caused by the loss- or gain-of-function of miRNAs, respectively. The stabilization of delivered oligonucleotides in vivo was the first critical hurdle to overcome. Various
vehicles or chemical modifications were designed and tested
from cells in culture, experimental animal models and
recently in clinical applications [70]. Table 1 summarizes the
important findings on the development of these techniques in
the context of liver-targeted delivery of miRNAs.
Viral Delivery of miRNAs in Liver Disease
Generally, the delivery methods of miRNAs can be classified into viral and non-viral systems. The advantage of
123
58
Curr Pathobiol Rep (2013) 1:53–62
Table 1 Summary of selected studies on the in vivo delivery of miRNA mimics or inhibitors
Delivery media
Target miR
Targeted disease
Animal model
Methods of
administration
Ref
Adeno-associated virus/
miRNA
miR-26
HCC
Myc-induced HCC
Intravenous
[64••]
20 -F/MOE modified antimir
miR-33
Atherosclerosis
Ldlr-/- mice
Subcutaneous
[34••]
LNA-modified antimir
Lipid Nanoparticles/
antagomirs
miR-33
miR-103,
107
Atherosclerosis
Type 2 diabetes
obesity
Western-diet fed mice
Chow-fed mice
Intravenous
Intravenous
[33•]
[98••]
LNA-modified antagomir
miR-122
Iron homeostasis
Chow-fed mice
Intraperitoneal
[99]
Adeno-associated virus/
miRNA
miR-122
HCC
Myc-induced HCC
Intravenous
[14••]
20 -O-Me antagomir
miR-122
Cholesterol
homeostasis
Chow-fed mice
Intravenous
[29]
20 -MOE modified antimir
miR-122
Obesity
Diet-induced obesity mice
Intraperitoneal
[28]
LNA modified antimir
miR-122
Hypercholesteroemia
Chow-fed mice/African green
monkeys
Intravenous/
Intraperitoneal
[38••]
LNA modified anti-mir
miR-122
HCV
Chimpanzee
Intravenous
[93••]
Lipid nanoparticle/miR
mimic
miR-124
HCC
DEN-induced HCC
Intravenous
[74]
viral delivery is that a single administration of recombinant
viral particles yields the long-term expression of specific
miRNAs of interest, and the infected cells need not be
replication proficient. The viral vector is constructed with
genes encoding the hairpin structure of miRNA under the
control of a promoter activated by RNA polymerase II.
Adeno-associated virus (AAV) is successfully used as the
vehicle to deliver miRNA to liver through systemic circulation [64•]. AAV simultaneously infects dividing and
non-diving cells with an infrequent or site-specific integration of its genes into host’s genome [71]. As mentioned
above, Kota et al. [64•] and Hsu et al. [14•] demonstrated
the AAV-mediated delivery of miR-26a and miR-122
precursor genes respectively to Myc-induced HCC model
successfully inhibited tumor growth. Similar approaches
can be applied to different types of cancers. For example,
Trang et al. [72] showed that adenoviral delivery of let-7a
through respiratory inhalation suppressed the tumor growth
to a murine lung tumor model.
Non-Viral Delivery of miRNAs in Liver Disease
Although viral delivery of miRNAs produces significant
ectopic expression of target genes, non-viral systems are
still considered a safer choice to prevent many adverse
effects of viruses, including immune system stimulation
and the risk of inducing oncogenic transformation [73].
Among the numerous chemical vehicles for the non-viral
delivery of RNAi, cationic lipid-based nanoparticles
(cLNPs) are widely used for therapy targeting the liver
123
[74–77, 78•, 79] and other organs [80–84]. Compared to a
neutral lipid system, the positively charged cLNPs can
easily interact with negatively charged miRNAs [85] to
form lipoplexes that prevent miRNAs from RNAse degradation in blood circulation, facilitate incorporation of
anionic miRNAs into anionic cell membranes, and promote
disruption of endosomal membrane to release engulfed
miRNAs [86, 87]. An important advance of liver-targeted
siRNA/miRNA delivery is the development of stable
nucleic-acid lipid particles (SNALP), which are natural
cationic lipid nanoparticles preferably taken up by the
liver. Upon reaching the liver, the SNALP could exit the
intravascular space to directly access hepatocytes as long
as the particle size is smaller than the pore size of the
fenestrated vasculature (100–150 nm in diameter) [88].
Zimmermann et al. [77] have used SNALP-mediated
delivery of siRNA to target hepatic APOB in non-human
primates. Notably, with a single intravenously injection
APOB in liver was reduced by 90 %, and the effect of
downregulation lasted for 11 days without causing significant tissue toxicity. SNALP has been tested in clinical
trials and may be used in clinic in the near future [89].
Delivery of miRNA Inhibitors
Compared to chemical-vehicle-mediated delivery of miR
mimics, delivery of miR inhibitors depends more on the
chemical modification of the inhibitors. Krutzfeldt
et al. [29] first demonstrated miR-122 knockdown in vivo
by the systemic delivery of an antagomirs, which is a
Curr Pathobiol Rep (2013) 1:53–62
20 -O-methyl-, phosphorothioate- modified, and cholesterol
conjugated oligoribonucleotides complementary to specific
microRNAs. This modification was also shown to effectively
deliver anti-miR-122 to liver and suppress the proliferation
of orthotopically xenografted tumor cells in mouse livers
[90]. The 20 -O-methyl modification was further improved by
locked nucleic acid (LNA) chemistry, in which there is an
extra bridge connecting the 20 oxygen and 40 carbon of
pentose, to render high binding affinity to complementary
RNA target molecules and high stability in blood and tissues
in vivo [91]. With LNA modification, the length of antimir
was shortened significantly to cover only the seed sequence
of selected miRNAs, resulting in much higher affinity
compared to the full-length antimirs [38••, 39]. LNA-modified antimirs have several other advantages, including low
off-target effects [92], efficient suppression of entire families
of miRNA [39], and broad distribution throughout different
organs after systemic delivery. The application of this LNA–
ASO was first tested in chimpanzees chronically infected
with HCV, which load titer without occurrence of mutated
virus escaped from treatment [93•]. However, our own and
other recent studies [14••, 15••] have highlighted the concern
that long-term inhibition of miR-122 may lead to the
development of hepatitis and liver cancer. Our data showed
that miR-122 liver-specific and germ line knockout mice
exhibited high incidences of HCC. According to our
unpublished data, about 15 % of heterozygous miR-122
knockout mice, which had 50 % reduction of miR-122 level,
developed HCC after a longer time period (*20 months)
than complete knockout mice (*12 months). Therefore,
HCV-infected patients undergoing Miravirsen therapy
should be routinely monitored for liver cancer development.
Conclusions and Future Directions
Gene therapy has been proposed and applied in some cases
to restore normal gene expression in liver disease. For
instance, gene therapy was proposed to treat HCC patients
without surgical removal of the tumor mass [94–96].
Although siRNA-mediated silencing of the expression of a
specific disease-causing target gene holds great promise for
gene therapy, it is likely that redundant genes with complementary functions could compensate for the function of
the knockdown gene. As an alternative strategy, miR-based
therapy is being intensely pursued because miRNAs can
target multiple genes. The fast growing discoveries of
miRNAs involved in liver physiology and pathophysiology
will greatly strengthen the therapeutic potential of gene
delivery based on miRNAs in treatment for liver disease.
Most of the studies relating miRs to a specific disease are
based on identifying and validating a few candidate targets
predicted by different databases. However, in the absence of
59
an unbiased transcriptomic and/or proteomic approach to
identify biological targets of miRNAs in specific cell types/
tissues, it is difficult to evaluate the molecular functions of
specific miRs in different diseases. Therefore, before
embarking on expensive clinical trials, it will be important
to perform bioinformatics-based analysis in a large number
of patients with different liver disease. The database of
disease-associated miRNA signatures will help to select the
best treatment option for patients with different patterns of
gene deregulation. For example, HCC patients with lowmiR-122 expression, as shown in many studies [14, 62, 97],
are more suitable for miR-122 delivery than patients with
high-miR-122 expression. In other words, the miR-122
delivery should not be a prioritized option for the treatment
of HCCs expressing a high level of miR-122.
Disclosure S. Hsu is supported by National Institutes of Health
(NIH) Grants to K. Ghoshal. K. Ghoshal is supported by Grants from
NIH, and has received honoraria for speaking engagements from
FASEB and University of Colorado in Denver.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Lee Y, Kim M, Han J et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23(20):4051–4060
2. Cai X, Hagedorn CH, Cullen BR (2004) Human microRNAs are
processed from capped, polyadenylated transcripts that can also
function as mRNAs. RNA 10(12):1957–1966
3. Bracht J, Hunter S, Eachus R et al (2004) Trans-splicing and
polyadenylation of let-7 microRNA primary transcripts. RNA
10(10):1586–1594
4. Han J, Lee Y, Yeom KH et al (2004) The Drosha-DGCR8
complex in primary microRNA processing. Genes Dev 18(24):
3016–3027
5. Lee Y, Ahn C, Han J et al (2003) The nuclear RNase III Drosha
initiates microRNA processing. Nature 425(6956):415–419
6. Lund E, Guttinger S, Calado A et al (2004) Nuclear export of
microRNA precursors. Science 303(5654):95–98
7. Haase AD, Jaskiewicz L, Zhang H et al (2005) TRBP, a regulator
of cellular PKR and HIV-1 virus expression, interacts with Dicer
and functions in RNA silencing. EMBO Rep 6(10):961–967
8. Lingel A, Sattler M (2005) Novel modes of protein-RNA recognition in the RNAi pathway. Curr Opin Struct Biol 15(1):
107–115
9. Winter J, Jung S, Keller S et al (2009) Many roads to maturity:
microRNA biogenesis pathways and their regulation. Nat Cell
Biol 11(3):228–234
10. Reinhart BJ, Slack FJ, Basson M et al (2000) The 21-nucleotide
let-7 RNA regulates developmental timing in Caenorhabditis
elegans. Nature 403(6772):901–906
11. Bernstein E, Kim SY, Carmell MA et al (2003) Dicer is essential
for mouse development. Nat Genet 35(3):215–217
123
60
12. • Sekine S, Ogawa R, Ito R et al: Disruption of Dicer1 induces
dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009, 136(7):2304–2315 e2301–2304.
This paper demonstrated loss of expression of miRs by the liver
specific deletion of Dicer1 directly promote hepatocarcinogenesis.
13. Hand NJ, Master ZR, Le Lay J, Friedman JR (2009) Hepatic
function is preserved in the absence of mature microRNAs.
Hepatology 49(2):618–626
14. •• Hsu SH, Wang B, Kota J et al (2012) Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR-122 in
liver. J Clin Investig. Together with ref#15, this study showed that
the liver specific or germline deletion of miR-122 directly
resulted in spontaneous HCC in mice. The deletion of miR-122
also induced steatohepatitis through the upregulation of target
genes, Agpat1 and Ccl2, respectively.
15. •• Tsai WC, Hsu SD, Hsu CS et al (2012) MicroRNA-122 plays a
critical role in liver homeostasis and hepatocarcinogenesis. J Clin
Investig. Together with ref#15, this study showed that the liver
specific or germline deletion of miR-122 directly resulted in
spontaneous HCC in mice. The deletion of miR-122 also induced
steatohepatitis through the upregulation of target genes, Agpat1
and Ccl2, respectively.
16. Hand NJ, Master ZR, Eauclaire SF et al (2009) The microRNA30 family is required for vertebrate hepatobiliary development.
Gastroenterology 136(3):1081–1090
17. Clotman F, Jacquemin P, Plumb-Rudewiez N et al (2005) Control
of liver cell fate decision by a gradient of TGF beta signaling
modulated by Onecut transcription factors. Genes Dev 19(16):
1849–1854
18. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B et al (1998)
Levels of transforming growth factor beta and transforming
growth factor beta receptors in rat liver during growth, regression
by apoptosis and neoplasia. Hepatology 28(3):717–726
19. Rogler CE, Levoci L, Ader T et al (2009) MicroRNA-23b cluster
microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by
targeting Smads. Hepatology 50(2):575–584
20. Popkin BM, Doak CM (1998) The obesity epidemic is a worldwide phenomenon. Nutr Rev 56(4 Pt 1):106–114
21. McGill HC Jr, McMahan CA, Herderick EE et al (2002) Obesity
accelerates the progression of coronary atherosclerosis in young
men. Circulation 105(23):2712–2718
22. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking
obesity to insulin resistance and type 2 diabetes. Nature 444
(7121):840–846
23. Ito S, Fujimori T, Furuya A et al (2005) Impaired negative
feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Investig 115(8):2202–2208
24. Fu T, Choi SE, Kim DH et al (2012) Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by
targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci
USA 109(40):16137–16142
25. Frost RJ, Olson EN (2011) Control of glucose homeostasis and
insulin sensitivity by the Let-7 family of microRNAs. Proc Natl
Acad Sci USA 108(52):21075–21080
26. Yamamoto M, Toya Y, Schwencke C et al (1998) Caveolin is an
activator of insulin receptor signaling. J Biological Chem 273
(41):26962–26968
27. Rottiers V, Naar AM (2012) MicroRNAs in metabolism and
metabolic disorders. Nat Rev Mol Cell Biol 13(4):239–250
28. Esau C, Davis S, Murray SF et al (2006) miR-122 regulation of
lipid metabolism revealed by in vivo antisense targeting. Cell
Metab 3(2):87–98
29. Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of
microRNAs in vivo with ‘antagomirs’. Nature 438(7068):
685–689
123
Curr Pathobiol Rep (2013) 1:53–62
30. Hardie DG (2003) Minireview: the AMP-activated protein kinase
cascade: the key sensor of cellular energy status. Endocrinology
144(12):5179–5183
31. Lee CG, Kim YW, Kim EH et al (2012) Farnesoid X receptor
protects hepatocytes from injury by repressing miR-199a-3p, which
increases levels of LKB1. Gastroenterology 142(5):1206–1217
e1207
32. Godlewski J, Nowicki MO, Bronisz A et al (2010) MicroRNA451 regulates LKB1/AMPK signaling and allows adaptation to
metabolic stress in glioma cells. Mol Cell 37(5):620–632
33. • Najafi-Shoushtari SH, Kristo F, Li Y et al (2010) MicroRNA-33
and the SREBP host genes cooperate to control cholesterol
homeostasis. Science 328(5985):1566–1569. This paper revealed
the role of miR-33 in the control of cholesterol homeostasis
through targeting ABCA1.
34. •• Rayner KJ, Sheedy FJ, Esau CC et al 2011 Antagonism of miR33 in mice promotes reverse cholesterol transport and regression of
atherosclerosis. J Clinical Investig 121(7):2921–2931. First study
to show the antimiR mediated miR-33 reduction reversed cholesterol transport and alleviate atherosclerosis in mouse model.
35. Rayner KJ, Esau CC, Hussain FN et al (2011) Inhibition of miR33a/b in non-human primates raises plasma HDL and lowers
VLDL triglycerides. Nature 478(7369):404–407
36. • Gatfield D, Le Martelot G, Vejnar CE et al (2009) Integration of
microRNA miR-122 in hepatic circadian gene expression. Genes
Dev 23(11):1313–1326. This paper showed that miR-122 was
tightly associated with control mechanisms regulating circadian
gene expression.
37. Jopling CL, Yi M, Lancaster AM et al (2005) Modulation of
hepatitis C virus RNA abundance by a liver-specific MicroRNA.
Science 309(5740):1577–1581
38. •• Elmen J, Lindow M, Schutz S et al (2008) LNA-mediated
microRNA silencing in non-human primates. Nature 452(7189):
896–899. This study demonstrated the therapeutic potential of
LNA-antimiRs by evaluating miRNA function after systemic administeration of LNA-antimiRs in rodents and primates.
39. Obad S, dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43(4):
371–378
40. Wang S, Qiu L, Yan X et al (2012) Loss of microRNA 122
expression in patients with hepatitis B enhances hepatitis B virus
replication through cyclin G(1) -modulated P53 activity. Hepatology 55(3):730–741
41. Guo H, Liu H, Mitchelson K et al (2011) MicroRNAs-372/373
promote the expression of hepatitis B virus through the targeting
of nuclear factor I/B. Hepatology 54(3):808–819
42. Bock CT, Kubicka S, Manns MP, Trautwein C (1999) Two
control elements in the hepatitis B virus S-promoter are important
for full promoter activity mediated by CCAAT-binding factor.
Hepatology 29(4):1236–1247
43. Lopez-Cabrera M, Letovsky J, Hu KQ, Siddiqui A (1990) Multiple liver-specific factors bind to the hepatitis B virus core/
pregenomic promoter: trans-activation and repression by CCAAT/
enhancer binding protein. Proc Natl Acad Sci USA 87(13):
5069–5073
44. Zhang X, Zhang E, Ma Z et al (2011) Modulation of hepatitis B
virus replication and hepatocyte differentiation by MicroRNA-1.
Hepatology 53(5):1476–1485
45. Menne S, Roneker CA, Korba BE et al (2002) Immunization with
surface antigen vaccine alone and after treatment with 1-(2fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil
(L-FMAU)
breaks humoral and cell-mediated immune tolerance in chronic
woodchuck hepatitis virus infection. J Virol 76(11):5305–5314
46. Walter E, Keist R, Niederost B et al (1996) Hepatitis B virus
infection of tupaia hepatocytes in vitro and in vivo. Hepatology
24(1):1–5
Curr Pathobiol Rep (2013) 1:53–62
47. Washburn ML, Bility MT, Zhang L et al (2011) A humanized
mouse model to study hepatitis C virus infection, immune
response, and liver disease. Gastroenterology 140(4):1334–1344
48. Zhang DY, Friedman SL (2012) Fibrosis-dependent mechanisms
of hepatocarcinogenesis. Hepatology 56(2):769–775
49. Ghiassi-Nejad Z, Hernandez-Gea V, Woodrell C et al (2012)
Reduced hepatic stellate cell expression of KLF6 tumor suppressor
isoforms amplifies fibrosis during acute and chronic rodent liver
injury. Hepatology. doi:10.1002/hep.26056. [Epub ahead of print].
50. Kodama T, Takehara T, Hikita H et al (2011) Increases in p53
expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Investig 121(8):
3343–3356
51. Roderburg C, Urban GW, Bettermann K et al (2011) Micro-RNA
profiling reveals a role for miR-29 in human and murine liver
fibrosis. Hepatology 53(1):209–218
52. Cushing L, Kuang PP, Qian J et al (2011) miR-29 is a major
regulator of genes associated with pulmonary fibrosis. Am J
Respir Cell Mol Biol 45(2):287–294
53. Kogure T, Costinean S, Yan I et al (2012) Hepatic miR-29ab1
expression modulates chronic hepatic injury. J Cell Mol Med
16(11):2647–2654
54. Seki E, De Minicis S, Osterreicher CH et al (2007) TLR4
enhances TGF-beta signaling and hepatic fibrosis. Nat Med
13(11):1324–1332
55. Friedman SL, Bansal MB (2006) Reversal of hepatic fibrosis: fact
or fantasy? Hepatology 43(2 Suppl 1):S82–S88
56. Ogawa T, Enomoto M, Fujii H et al (2012) MicroRNA-221/222
upregulation indicates the activation of stellate cells and the
progression of liver fibrosis. Gut 61(11):1600–1609
57. Galardi S, Mercatelli N, Farace MG, Ciafre SA (2011) NF-kB
and c-Jun induce the expression of the oncogenic miR-221 and
miR-222 in prostate carcinoma and glioblastoma cells. Nucleic
Acids Res 39(9):3892–3902
58. Lee KS, Buck M, Houglum K, Chojkier M (1995) Activation of
hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Investig
96(5):2461–2468
59. Lang A, Schoonhoven R, Tuvia S et al (2000) Nuclear factor
kappaB in proliferation, activation, and apoptosis in rat hepatic
stellate cells. J Hepatol 33(1):49–58
60. Kutay H, Bai S, Datta J et al (2006) Downregulation of miR-122
in the rodent and human hepatocellular carcinomas. J Cell Biochem 99(3):671–678
61. Bai S, Nasser MW, Wang B et al (2009) MicroRNA-122 inhibits
tumorigenic properties of hepatocellular carcinoma cells and
sensitizes these cells to sorafenib. J Biological Chem 284(46):
32015–32027
62. Hou J, Lin L, Zhou W et al (2011) Identification of miRNomes in
human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell
19(2):232–243
63. Ji J, Shi J, Budhu A et al (2009) MicroRNA expression, survival,
and response to interferon in liver cancer. N Engl J Med 361(15):
1437–1447
64. •• Kota J, Chivukula RR, O’Donnell KA et al (2009) Therapeutic
microRNA delivery suppresses tumorigenesis in a murine liver
cancer model. Cell 137(6):1005–1017. The first study to show the
viral mediated delivery of microRNA is efficient in the suppression of sponaneous liver tumor with a mouse model.
65. Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21
regulates expression of the PTEN tumor suppressor gene in
human hepatocellular cancer. Gastroenterology 133(2):647–658
66. Wang B, Majumder S, Nuovo G et al (2009) Role of microRNA-155
at early stages of hepatocarcinogenesis induced by choline-deficient
61
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
and amino acid-defined diet in C57BL/6 mice. Hepatology 50(4):
1152–1161
Wang B, Hsu SH, Majumder S et al (2010) TGFbeta-mediated
upregulation of hepatic miR-181b promotes hepatocarcinogenesis
by targeting TIMP3. Oncogene 29(12):1787–1797
Gabriely G, Wurdinger T, Kesari S et al (2008) MicroRNA 21
promotes glioma invasion by targeting matrix metalloproteinase
regulators. Mol Cell Biol 28(17):5369–5380
Garofalo M, Di Leva G, Romano G et al (2009) miR-221&222
regulate TRAIL resistance and enhance tumorigenicity through
PTEN and TIMP3 downregulation. Cancer Cell 16(6):498–509
Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics:
an emerging treatment modality for cancer. Nat Rev Drug Discov
7(9):771–782
Daya S, Berns KI (2008) Gene therapy using adeno-associated
virus vectors. Clin Microbiol Rev 21(4):583–593
Trang P, Medina PP, Wiggins JF et al (2010) Regression of murine
lung tumors by the let-7 microRNA. Oncogene 29(11):1580–1587
Cunningham AP, Andrews LG, Tollefsbol TO (2007) Retrovirusmediated RNA interference. Targeting hTERT through stable
expression of short-hairpin RNA. Methods Mol Biol 405:39–46
Hatziapostolou M, Polytarchou C, Aggelidou E et al (2011) An
HNF4alpha-miRNA inflammatory feedback circuit regulates
hepatocellular oncogenesis. Cell 147(6):1233–1247
Sonoke S, Ueda T, Fujiwara K et al (2011) Galactose-modified
cationic liposomes as a liver-targeting delivery system for small
interfering RNA. Biological Pharm Bull 34(8):1338–1342
Yano J, Hirabayashi K, Nakagawa S et al (2004) Antitumor
activity of small interfering RNA/cationic liposome complex in
mouse models of cancer. Clin Cancer Res 10(22):7721–7726
Zimmermann TS, Lee AC, Akinc A et al (2006) RNAi-mediated
gene silencing in non-human primates. Nature 441(7089):111–114
• Semple SC, Akinc A, Chen J et al (2010) Rational design of
cationic lipids for siRNA delivery. Nature biotechnol
28(2):172–176. This paper demonstrated the application of a newly
designed SNALP in siRNA-mediated hepatic gene silencing.
Akinc A, Querbes W, De S et al (2010) Targeted delivery of
RNAi therapeutics with endogenous and exogenous ligand-based
mechanisms. Mol Ther 18(7):1357–1364
Chen Y, Zhu X, Zhang X et al (2010) Nanoparticles modified
with tumor-targeting scFv deliver siRNA and miRNA for cancer
therapy. Mol Ther 18(9):1650–1656
Pramanik D, Campbell NR, Karikari C et al (2011) Restitution of
tumor suppressor microRNAs using a systemic nanovector
inhibits pancreatic cancer growth in mice. Mol Cancer Ther
10(8):1470–1480
Akao Y, Nakagawa Y, Hirata I et al (2010) Role of anti-oncomirs
miR-143 and -145 in human colorectal tumors. Cancer Gene Ther
17(6):398–408
Piao L, Zhang M, Datta J et al (2012) Lipid-based nanoparticle
delivery of Pre-miR-107 inhibits the tumorigenicity of head and
neck squamous cell carcinoma. Mol Ther 20(6):1261–1269
Wu Y, Crawford M, Yu B et al (2011) MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 8(4):1381–1389
Sioud M, Sorensen DR (2003) Cationic liposome-mediated
delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312(4):1220–1225
Liu Y, Huang L (2010) Designer lipids advance systemic siRNA
delivery. Mol Ther 18(4):669–670
Hafez IM, Maurer N, Cullis PR (2001) On the mechanism
whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8(15):1188–1196
Wisse E, Jacobs F, Topal B et al (2008) The size of endothelial
fenestrae in human liver sinusoids: implications for hepatocytedirected gene transfer. Gene Ther 15(17):1193–1199
123
62
89. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of
siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6(9):
1130–1146
90. Park JK, Kogure T, Nuovo GJ et al (2011) miR-221 silencing
blocks hepatocellular carcinoma and promotes survival. Cancer
Res 71(24):7608–7616
91. Fluiter K, ten Asbroek AL, de Wissel MB et al (2003) In vivo
tumor growth inhibition and biodistribution studies of locked
nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids
Res 31(3):953–962
92. You Y, Moreira BG, Behlke MA, Owczarzy R (2006) Design of
LNA probes that improve mismatch discrimination. Nucleic
Acids Res 34(8):e60
93. • Lanford RE, Hildebrandt-Eriksen ES, Petri A et al (2010)
Therapeutic silencing of microRNA-122 in primates with chronic
hepatitis C virus infection. Science 327(5962):198–201. First
evidence to show the silencing of miR-122 by LNA modified antimir can be used to inbhit HCV infection in primates.
94. Ghosh SS, Takahashi M, Thummala NR et al (2000) Liverdirected gene therapy: promises, problems and prospects at the
turn of the century. J Hepatol 32(1 Suppl):238–252
123
Curr Pathobiol Rep (2013) 1:53–62
95. Jin X, Yang YD, Li YM (2008) Gene therapy: regulations, ethics
and its practicalities in liver disease. World J Gastroenterol
14(15):2303–2307
96. Anderson WF (1998) Human gene therapy. Nature 392(6679
Suppl):25–30
97. Coulouarn C, Factor VM, Andersen JB et al (2009) Loss of miR122 expression in liver cancer correlates with suppression of the
hepatic phenotype and gain of metastatic properties. Oncogene
28(40):3526–3536
98. •• Trajkovski M, Hausser J, Soutschek J et al (2011) MicroRNAs 103
and 107 regulate insulin sensitivity. Nature 474(7353):649–653.
First study to show the therapeutic potential of antagomir mediated
miR-103/107 reduction that improved glucose homeostasis and
insulin sensitivity.
99. Castoldi M, Vujic Spasic M, Altamura S et al (2011) The liverspecific microRNA miR-122 controls systemic iron homeostasis
in mice. J Clin Investig 121(4):1386–1396